Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

(2021) Massimo Cristofanilli et al.   JOURNAL OF CLINICAL ONCOLOGY

177P Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Germany: Results from the IRIS study

(2020) G. Taylor-Stokes et al.   ANNALS OF ONCOLOGY

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

(2020) Elise Deluche et al.   EUROPEAN JOURNAL OF CANCER

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

(2018) Nadia Howlader et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Hormone receptor–positive, HER2-negative metastatic breast cancer: redrawing the lines

(2018) A. Matutino et al.   Current Oncology

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

(2018) Anishka D’Souza et al.   Journal of Hematology & Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study

(2018) Gavin Taylor-Stokes et al.   BREAST

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE